RLAY 241220 2.50C (RLAY241220C2500) Stock Options, News & Quotes

US OptionsDetailed Quotes

RLAY241220C2500

Watchlist

4.40
0.000.00%

15min DelayTrading May 28 13:21 ET

0.00High0.00Low

Intraday

5D
Daily

News

Down -23.95% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround
Zacks Nov 19 09:00 ET
H.C. Wainwright Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $20
Moomoo NewsNov 9 05:33 ET · Ratings
A Quick Look at Today's Ratings for Relay Therapeutics(RLAY.US), With a Forecast Between $17 to $27
Moomoo NewsNov 8 08:00 ET · Ratings
Relay Therapeutics Price Target Raised to $20 From $19 at H.C. Wainwright
TipRanksNov 8 06:30 ET
Barclays Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $17
Moomoo NewsNov 7 03:31 ET · Ratings
JMP Securities Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $21
Moomoo NewsNov 7 01:32 ET · Ratings

Comments

Options Newsman

Oct 1 20:25

Columns Options Market Statistics: Options Popped as Investors Placed Bets Before Nike Revealed Earnings

News Highlights
$Meta Platforms (META.US)$ shares increased 0.70%, with with option volume of 0.37 million, and calls accounted for 58.2% of the volume. The $585 calls expiring October 4 were traded most actively.
Meta Platforms said on Tuesday that the company will expand artificial intelligence investment in Vietnam, including production of its mixed reality Quest 3S headsets in the country from next...

Newbee4

Sep 10 09:23

Retreats on planned equity offering

$Relay Therapeutics (RLAY.US)$

103317720

Sep 10 09:04

$Relay Therapeutics (RLAY.US)$ Did they just pump and dump?

Newbee4

Sep 9 19:09

$20

$Relay Therapeutics (RLAY.US)$

Goldman Sachs Upgrades Relay Therapeutics(RLAY.US) to Buy Rating, Announces Target Price $20

Trytosaveabit

Sep 9 15:42

OFFERING

$Relay Therapeutics (RLAY.US)$ CAMBRIDGE, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc.(NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced today that it has commenced an underwritten public offering of $200 million of shares of its common stock. Relay Therapeutics also intends to grant the underwriters a 30-day option to purchase up to an add...